Scarica l'app Stockscreener
7.57
2.16%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Precedente Chiudi:
$7.41
Aprire:
$7.5615
Volume 24 ore:
40,316
Relative Volume:
0.66
Capitalizzazione di mercato:
$46.58M
Reddito:
$2.19M
Utile/perdita netta:
$-24.19M
Rapporto P/E:
-0.8801
EPS:
-8.6017
Flusso di cassa netto:
$-82.94M
1 W Prestazione:
+8.45%
1M Prestazione:
+9.55%
6M Prestazione:
-25.78%
1 anno Prestazione:
-26.36%
Intervallo 1D:
$7.50
$7.9027
Intervallo di 1 settimana:
$6.56
$8.00
Portata 52W:
$3.76
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Nome
Aligos Therapeutics Inc
Settore
Industria
Telefono
(800) 466-6059
Indirizzo
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.57 | 46.58M | 2.19M | -24.19M | -82.94M | -8.6017 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-18 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-19 | Iniziato | H.C. Wainwright | Buy |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-09 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Ripresa | Piper Sandler | Overweight |
| 2020-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Iniziato | JP Morgan | Overweight |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Precision Trading with Aligos Therapeutics Inc. (ALGS) Risk Zones - Stock Traders Daily
Aligos Therapeutics (ALGS) accounting officer granted 9,450 stock options at $7.03 - Stock Titan
Aligos Therapeutics (ALGS) CEO granted stock options for 105,840 shares - Stock Titan
HC Wainwright & Co. Reiterates Buy Rating on ALGS with $50 Price Target | ALGS Stock News - GuruFocus
Dip Buying: Can Aligos Therapeutics Inc weather a recessionWeekly Earnings Recap & Risk Managed Trade Strategies - baoquankhu1.vn
Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen - Defense World
Aug Highlights: Can Aligos Therapeutics Inc weather a recessionMarket Rally & Daily Entry Point Alerts - baoquankhu1.vn
Aligos Therapeutics Earnings Report: Q4 Overview - Sahm
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - Bitget
Aligos Therapeutics (ALGS) Reports Lower Q4 Revenue and Advances Key Studies - GuruFocus
ALIGOS THERAPEUTICS ($ALGS) Releases Q4 2025 Earnings - Quiver Quantitative
Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing - TradingView
Aligos Therapeutics Q4 net loss narrows - TradingView
Growth Report: Will Aligos Therapeutics Inc benefit from current market trendsM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Big loss reduction as Aligos (NASDAQ: ALGS) advances HBV and obesity pipeline - Stock Titan
ALGS SEC FilingsAligos Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
A Peek at Aligos Therapeutics's Future Earnings - Benzinga
ALGS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Monday - Defense World
9 Pharma Trends To Watch In 2026 - Pharmaceutical Online
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play - TipRanks
Aligos Therapeutics Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 - The Manila Times
Aligos Therapeutics (ALGS) Reports Encouraging Findings at CROI 2026 - GuruFocus
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - The Manila Times
Aligos Therapeutics, Inc. Reports Positive Data from CROI Presentations on Pevifoscorvir Sodium and ALG-097558 - Quiver Quantitative
Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan
Risk On: What is ILMNs P E ratio telling usJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Moving Averages: What analysts say about Aligos Therapeutics Inc stockMarket Growth Review & Fast Momentum Entry Tips - baoquankhu1.vn
Can Aligos Therapeutics Inc. continue delivering strong returnsRecession Risk & Trade Opportunity Analysis Reports - mfd.ru
Trading the Move, Not the Narrative: (ALGS) Edition - Stock Traders Daily
Officer stock option holdings disclosed at Aligos Therapeutics (ALGS) - Stock Titan
Woodline Partners reports 5.4% Aligos (ALGS) stake in amended 13G - Stock Titan
Will Aligos Therapeutics Inc. benefit from current market trends2025 Stock Rankings & AI Forecast Swing Trade Picks - mfd.ru
What are the future prospects of DWSNMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Aligos Therapeutics Inc. weather a recessionMarket Weekly Review & Daily Profit Maximizing Trade Tips - mfd.ru
ALGS Should I Buy - Intellectia AI
Rally Mode: What analysts say about Aligos Therapeutics Inc stockMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Aligos Therapeutics: Pipeline Progress and Financial Runway Under the Microscope - AD HOC NEWS
(ALGS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aligos Therapeutics Appoints New Principal Accounting Officer - The Globe and Mail
Aligos Therapeutics Grants Non-Qualified Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Aligos gives new hires options on 81,100 shares - Stock Titan
Aligos Therapeutics (ALGS) Awards Stock Options to New Employees - GuruFocus
Aligos Therapeutics secures $105 million in private placement - MSN
Price-Driven Insight from (ALGS) for Rule-Based Strategy - Stock Traders Daily
Aligos Therapeutics edges higher after update on Phase 2 HBV trial - MSN
Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress - Investing.com
Aligos Therapeutics Inc Azioni (ALGS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):